DPP-4 inhibitors were observed to be related with a decreased incidence of HCC in individuals with Type 2 Diabetes Mellitus (DM) with chronic HCV or HBV infection in two Taiwanese studies (59, 60). Here, DPP4 is linked to type 2 diabetes mellitus.